Leerink Partners Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $44
Leerink Partners Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $44
Leerink Partners維持對rocket pharmaceuticals的跑贏大盤評級,調整目標股價至44美元。
Leerink Partners analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $46 to $44.
Leerink Partners的分析師Mani Foroohar對rocket pharmaceuticals (納斯達克:RCKT)維持跑贏大市評級,並將目標價從46美元下調至44美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。